by Market Overview:
Preeclampsia diagnostics include tests and analysis to diagnose preeclampsia during pregnancy. It is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. The diagnosis is based on new onset of high blood pressure and protein in the urine or other signs of organ dysfunction arising after 20 weeks of pregnancy in a woman with previously normal blood pressure.
The Preeclampsia Diagnostics market is estimated to be valued at US$ 1,587.53 Mn or Mn in 2023 and is expected to exhibit a CAGR of 11.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growth of the preeclampsia diagnostics market is driven by the increasing incidence of preeclampsia during pregnancy globally. According to World Health Organization (WHO), preeclampsia/eclampsia is one of the leading causes of maternal and neonatal morbidity and mortality, accounting for ~14% of all maternal deaths globally each year. It is estimated that around 5-8% of pregnancies are complicated by preeclampsia globally. Early diagnosis of preeclampsia is crucial to improve maternal and fetal outcomes. Development and commercialization of novel diagnostic solutions with high sensitivity and specificity is expected to boost early detection of preeclampsia. However, shortage of skilled healthcare professionals in developing regions may hamper market growth.
Segment Analysis
The global preeclampsia diagnostics market is segmented into product, test type, and end user. Based on product, the market is divided into instruments, consumables, and others. Consumables are further segmented into immunoassay kits and biochemistry test panels. The consumables segment currently dominates the market due to the frequent usage of consumables for diagnosis.
PEST Analysis
Political: Regulations regarding women’s healthcare and routine screening for preeclampsia during pregnancy are expected to drive the market.
Economic: Rising healthcare expenditures globally is anticipated to boost the adoption of advanced preeclampsia diagnostics tests.
Social: Increasing awareness about preeclampsia, its complications and availability of diagnostic tests is predicted to spur the market growth.
Technological: Continuous developments in assay procedures, immunoassay kits and biochemistry panels are estimated to offer new opportunities.
Key Takeaways
The Global Preeclampsia Diagnostics Market Size is expected to witness high growth, exhibiting a CAGR of 11.8% over the forecast period, due to increasing incidence of preeclampsia and rise in routine screening.
The North America region holds the largest market and is expected to maintain its dominating position during the forecast period. Increasing awareness about preeclampsia diagnosis and availability of advanced healthcare facilities are factors boosting the North America market.
Europe is predicted to showcase significant growth due to rising research funding for improving preeclampsia diagnosis. The Asia Pacific region exhibits the fastest growth rate owing to growing healthcare expenditure and rising medical tourism.
Key players operating in the preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc. These players are focusing on new product launches and regional expansions to increase their market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
